Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 8
Submit an article Journal homepage
259
Views
8
CrossRef citations to date
0
Altmetric
Letters to the Editor

miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia

Suganthi S. RamachandranDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India;
,
Pamchui MuiwoSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India;
,
Hafiz M. AhmadDepartment of Cancer Cell and Molecular Biology, University of Massachusetts Medical School, Worcester, MA, USA;
,
Ravindra Mohan PandeyDepartment of Biostatistics, All India Institute of Medical Sciences, New Delhi, India;
,
Surender SinghDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India;
,
Sameer BakhshiDepartment of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India
,
Lalit KumarDepartment of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India
,
Alok BhattacharyaSchool of Life Sciences, Jawaharlal Nehru University, New Delhi, India;
&
Yogendra Kumar GuptaDepartment of Pharmacology, All India Institute of Medical Sciences, New Delhi, India; Correspondence[email protected]
 show all
Pages 1981-1984 | Received 24 Jul 2016, Accepted 10 Dec 2016, Published online: 16 Jan 2017

References

  • Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22:1963–1966.
  • San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69.
  • Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95:1325–1333.
  • Vaz C, Ahmad HM, Sharma P, et al. Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood. BMC Genomics. 2010;11:1.
  • Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
  • Yamamoto Y, Yoshioka Y, Minoura K, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer. 2011;10:1.
  • Chen S, Sun K-X, Liu B-L, et al. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer. 2016;15:11.
  • Nievergall E, Reynolds J, Kok CH, et al. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016;30:1263–1272.
  • Haetscher N, Feuermann Y, Wingert S, et al. STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling. Nat Comms. 2015;6:8928.
  • Mets E, Van der Meulen J, Van Peer G, et al. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia. Leukemia. 2015;29:798–806.
  • Li H, Xu Y, Qiu W, et al. Tissue miR-193b as a Novel Biomarker for Patients with Ovarian Cancer. Med Sci Monit. 2015;21:3929–3934.
  • Humphreys KJ, McKinnon RA, Michael MZ. miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PLoS One. 2014;9:e112288.
  • Scherr M, Elder A, Battmer K, et al. Differential expression of miR-17 ∼ 92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia. 2014;28:554–565.
  • Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109:4399–4405.
  • Jurkovicova D, Lukackova R, Magyerkova M, et al. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma. 2015;62:949–958.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.